论文部分内容阅读
目的:探讨肿瘤石蜡组织中ERCC1 codon118单核苷酸多态性(single nucleotide polymorphism,SNP)与接受铂类药物化疗非小细胞肺癌(chemotherapy;non-small-cell lung cancer,NSCLC)患者临床预后之间的关系。方法:采用聚合酶链反应-限制性内切酶片段长度多态性(PCR-RFLP)的方法评价47例石蜡包埋NSCLC肿瘤组织中DNA修复基因ERCC1第118位密码子的单核苷酸多态性,并比较不同基因型与NSCLC组织临床病理及铂类化疗预后之间的关系。结果:所有NSCLC患者中位生存时间为16.0月(95%CI,16.4-28.4月),中位无进展生存期为8.0月(95%CI,9.4-16.9月)。ERCC1 codon118与NSCLC临床病理特征均未见相关性。携带ERCC1 C/C基因型的NSCLC患者的中位总生存时间为25.0月,而携带C/T及T/T基因型患者的中位总生存时间仅为10.5月,两者有统计学差异(P=0.012)。携带ERCC1 C/C基因型的NSCLC患者的中位无进展生存期为13.2月,而携带C/T及T/T基因型患者的中位无进展生存期仅为6.0月,两者有统计学差异(P=0.029)。结论:ERCC1 codon118基因单核苷酸多态性与接受铂类药物化疗的NSCLC患者的总生存时间和无进展生存期有关,在一定程度上可以作为判断NSCLC患者铂类药物化疗的预后指标。
Objective: To investigate the relationship between ERCC1 codon118 single nucleotide polymorphism (SNP) and clinical prognosis of patients with platinum-based chemotherapy chemotherapy for non-small-cell lung cancer (NSCLC) Relationship between. Methods: PCR-RFLP was used to assess the single nucleotide polymorphism of codon 118 of ERCC1 gene in 47 cases of NSCLC with paraffin embedded The relationship between different genotypes and clinical pathology and prognosis of NSCLC was compared. RESULTS: The median overall survival for all patients with NSCLC was 16.0 months (95% CI, 16.4-28.2 months) and median progression-free survival was 8.0 months (95% CI, 9.4-16.9 months). There was no correlation between ERCC1 codon118 and clinicopathological features of NSCLC. The overall median overall survival was 25.0 months in patients with NSCLC carrying the C / C genotype of ERCC1 and 10.5 months in those with C / T and T / T genotypes, both of which were statistically different P = 0.012). The median progression-free survival of NSCLC patients with ERCC1 C / C genotype was 13.2 months, while the median progression-free survival of patients with C / T and T / T genotypes was only 6.0 months, both of which were statistically significant Difference (P = 0.029). Conclusion: The single nucleotide polymorphism of ERCC1 codon118 gene is associated with the overall survival and progression-free survival of patients with NSCLC receiving platinum-based chemotherapy. To some extent, it can be used as a prognostic indicator for the chemotherapy of platinum-based chemotherapy in patients with NSCLC.